CSNK2A2

Casein kinase II subunit alpha' · P19784 · CSNK2A2 on Sugi Atlas →

114,262 patent compounds predicted against CSNK2A2, 78,415 high-confidence (nearest known ligand ≥ 0.5)

Top predicted compounds (top 20 by supporting neighbours, then confidence)

Compound	Confidence	Supporting neighbours
SCHEMBL71021	0.59	6/20
SCHEMBL79794	0.41	6/20
Quercetin (SCHEMBL19723)	1.00	5/20
Quercetin (SCHEMBL118425)	1.00	5/20
Kaempferol (SCHEMBL18817)	1.00	4/20
Myricetin (SCHEMBL19302)	1.00	4/20
Morin (SCHEMBL19984)	1.00	4/20
Chrysin (SCHEMBL44474)	1.00	4/20
Quercetin (SCHEMBL22103)	0.97	4/20
Galangin (SCHEMBL117225)	0.81	4/20
Datiscetin (SCHEMBL43916)	0.78	4/20
Quercetin (SCHEMBL111510)	0.76	4/20
SCHEMBL117527	0.67	4/20
SCHEMBL120585	0.65	4/20
SCHEMBL50925	0.43	4/20
SCHEMBL8307	0.39	4/20
Mitoxantrone (SCHEMBL3000)	1.00	3/20
Apigenin (SCHEMBL19428)	1.00	3/20
Luteolin (SCHEMBL20426)	1.00	3/20
Quinalizarin (SCHEMBL138122)	1.00	3/20

Clinical trials — most relevant to CSNK2A2 by text similarity (a relevance ranking, not an exhaustive list)

Trial	Phase	Status
The G Protein-Coupled Receptor Kinase Type 2 Inhibitor Paroxetine as Adjunctive Therapy to Improve Insulin Sensitivity in Patients With Type 2 Diabetes Mellitus	PHASE3	UNKNOWN
Treatment With HMG-COA Reductase Inhibitor of Growth and Bone Abnormalities in Children With Noonan Syndrome	PHASE3	COMPLETED
Evaluating Safety, Pharmacokinetics and Clinical Benefit of Silmitasertib (CX-4945) in Subjects With Moderate COVID-19	PHASE2	COMPLETED
Letrozole, Herceptin in Her2neu +, Estrogen Receptor [ER] and/or Progesterone Receptor [PR] Positive, MBC	PHASE2	COMPLETED
Doxycycline in Human Pulmonary Tuberculosis	PHASE2	COMPLETED
Autologous Cytokine Induced Killer Cells (CIK) for Chronic Myeloid Leukemia (CML) Patients on Standard Drug Therapy	PHASE2	COMPLETED
Dose-escalation Study of Oral CX-4945	PHASE1	UNKNOWN
Temsirolimus and Sorafenib in Advanced Hepatocellular Carcinoma	PHASE1	COMPLETED
Bristol-Myers Squibb Dasatinib Src Inhibition in Endometrial Cancer	EARLY_PHASE1	COMPLETED
Defining the Triple Negative Breast Cancer Kinome Response to GSK1120212	EARLY_PHASE1	COMPLETED
Identification of Novel Targetable Kinases in SR-a GvHD	nan	COMPLETED
Study of Metabolic Modifications in Children With Noonan Syndrome	nan	COMPLETED
Study of a Candidate Gene Involved in Goldenhar Syndrome.	nan	COMPLETED
New Genes Involved in Molecular Etiology of Rett Syndrome Through DNA Microarray Comparative Genomic Hybridization	nan	COMPLETED
Nuclear Myosin VI - a Therapeutic Target in Breast Cancer	nan	UNKNOWN
Ischemic Preconditioning - Perspectives of Use Vivio/in Vitro Studies	nan	ENROLLING_BY_INVITATION
Genetic Investigations in Children With Developmental and Epileptic Encephalopathies in Ho Chi Minh City, Vietnam	nan	UNKNOWN
The Relation of Microtubule-Associated Protein 2 and Cell Migration	nan	UNKNOWN
Determining the Association of Chromosomal Variants With Non-PV Triggers and Ablation-outcome in AF (DECAF)	nan	COMPLETED
Family Blood Pressure Program - HyperGEN	nan	COMPLETED
Diagnosis of RSTS: Identification of the Acetylation Profiles as Epigenetic Markers for Assessing Causality of CREBBP and EP300 Variants.	nan	UNKNOWN
Investigation of the Genetic Causes of Kallmann Syndrome and Reproductive Disorders	nan	COMPLETED
Clinical Characterization of Frequent Monogenic Forms of Neurodevelopmental Disorders	nan	UNKNOWN
Clinical and Genetic Analysis in Congenital Hypothyroidism Due to Thyroid Dysgenesis.	nan	COMPLETED
Family Blood Pressure Program - GenNet Network	nan	COMPLETED
JAK-STAT Signalling Pathway in Familial Myeloproliferative Disorders	nan	COMPLETED
Immune Signature of Palmoplantar Pustulosis	nan	COMPLETED
Family Blood Pressure Program - GENOA	nan	COMPLETED
Hemodynamic Assessment of underLying myocyTe Function in Right Heart Failure	nan	RECRUITING
Avapritinib in the Treatment of Unresectable or Recurrent Metastatic GIST Non-exon18 Mutations of PDGFRA	nan	RECRUITING

Related proteins — ESM-2 sequence neighbours (a CSNK2A2 binder may also engage these)

Protein	Name	Similarity
O54833	—	1.000	O54833 →
P20427	—	1.000	P20427 →
P21869	—	1.000	P21869 →
Q9AR27	—	0.986	Q9AR27 →
O76484	—	0.986	O76484 →
B6F107	—	0.986	B6F107 →
P08181	—	0.983	P08181 →
P28523	—	0.982	P28523 →
CSNK2A1	Casein kinase II subunit alpha	0.975	landscape →
P33674	—	0.973	P33674 →
P68399	—	0.972	P68399 →
P21868	—	0.972	P21868 →
P28020	—	0.970	P28020 →
CSNK2A3	Casein kinase II subunit alpha 3 (CK II alpha	0.970	landscape →
Q60737	—	0.969	Q60737 →
P19139	—	0.969	P19139 →
O64817	—	0.967	O64817 →
P18334	—	0.966	P18334 →
Q8TG13	—	0.959	Q8TG13 →
Q9DGD9	—	0.958	Q9DGD9 →
MAPKAPK2	MAP kinase-activated protein kinase 2	0.956	landscape →
Q7XQP4	—	0.954	Q7XQP4 →
P49138	—	0.954	P49138 →
A9TF79	—	0.952	A9TF79 →
Q9FFP9	—	0.951	Q9FFP9 →
Q6ZI44	—	0.950	Q6ZI44 →
A2YNT8	—	0.949	A2YNT8 →
P49139	—	0.949	P49139 →
P43292	—	0.949	P43292 →
MAPKAPK3	MAP kinase-activated protein kinase 3	0.949	landscape →